ℹ️
🇬🇧
Search
Search for publications relevant for "teriflunomide"
teriflunomide
Publication
Class
Person
Publication
Programmes
publication
Teriflunomid
2014 |
First Faculty of Medicine
publication
Teriflunomidu position in the treatment of multiple sclerosis
2018 |
Faculty of Medicine in Hradec Králové
publication
Renal cell carcinoma
2015 |
First Faculty of Medicine
publication
Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide
2022 |
First Faculty of Medicine
publication
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
2021 |
First Faculty of Medicine
publication
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
2019 |
First Faculty of Medicine
publication
Pharmacovigilance new medicines for the treatment of multiple sclerosis
2016 |
First Faculty of Medicine
publication
Current possibilities and principles of pharmacotherapy in relapsing-remitting multiple sclerosis
2014 |
Publication without faculty affiliation
publication
Teriflunomide Is an Indirect Human Constitutive Androstane Receptor (CAR) Activator Interacting With Epidermal Growth Factor (EGF) Signaling
2018 |
Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
publication
Možnosti biologické léčby u roztroušené sklerózy
2015 |
Publication without faculty affiliation
publication
Does the development of new drugs for multiple sclerosis change the prognosis of the patient ?
2011 |
First Faculty of Medicine
publication
Does the development of new drugs for multiple sclerosis change the prognosis of the patient?
2011 |
First Faculty of Medicine
publication
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis
2016 |
First Faculty of Medicine
publication
Immunosuppressive drugs in treating neurological diseases
2011 |
Publication without faculty affiliation
publication
Comparison of long-term results of treatment, depending on the cumulative dose of IFN-β1a administered subcutaneously in different groups of patients with multiple sclerosis: an analysis of PRISMS-15 trial
2016 |
Publication without faculty affiliation
publication
Ofatumumab
2021 |
First Faculty of Medicine
publication
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry
2023 |
First Faculty of Medicine
publication
A comparison of efficacy of subcutaneous interferon beta-1a 44 mu g, dimethyl fumarate and fingolimod in the real-life clinical practise - a multicenter observational study
2018 |
First Faculty of Medicine, Faculty of Medicine in Hradec Králové
publication
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
2023 |
First Faculty of Medicine
publication
Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS
2021 |
Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Second Faculty of Medicine, Third Faculty of Medicine
publication
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison
2014 |
First Faculty of Medicine
publication
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
2023 |
First Faculty of Medicine
publication
IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis
2022 |
Second Faculty of Medicine
publication
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity
2023 |
First Faculty of Medicine
publication
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
2021 |
First Faculty of Medicine
publication
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
2022 |
First Faculty of Medicine
publication
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
2024 |
First Faculty of Medicine